Cargando…

Predictors of Clinically Significant Prostate Cancer in Patients with PIRADS Categories 3–5 Undergoing Magnetic Resonance Imaging-Ultrasound Fusion Biopsy of the Prostate

Prostate biopsy is recommended in cases of positive magnetic resonance imaging (MRI), defined as Prostate Imaging Reporting and Data System (PIRADS) category ≥ 3. However, most men with positive MRIs will not be diagnosed with clinically significant prostate cancer (csPC). Our goal was to evaluate p...

Descripción completa

Detalles Bibliográficos
Autores principales: Szempliński, Stanisław, Kamecki, Hubert, Dębowska, Małgorzata, Zagożdżon, Bartłomiej, Mokrzyś, Mateusz, Zawadzki, Marek, Sosnowski, Roman, Tokarczyk, Andrzej, Poletajew, Sławomir, Kryst, Piotr, Nyk, Łukasz
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820960/
https://www.ncbi.nlm.nih.gov/pubmed/36614957
http://dx.doi.org/10.3390/jcm12010156
_version_ 1784865584578560000
author Szempliński, Stanisław
Kamecki, Hubert
Dębowska, Małgorzata
Zagożdżon, Bartłomiej
Mokrzyś, Mateusz
Zawadzki, Marek
Sosnowski, Roman
Tokarczyk, Andrzej
Poletajew, Sławomir
Kryst, Piotr
Nyk, Łukasz
author_facet Szempliński, Stanisław
Kamecki, Hubert
Dębowska, Małgorzata
Zagożdżon, Bartłomiej
Mokrzyś, Mateusz
Zawadzki, Marek
Sosnowski, Roman
Tokarczyk, Andrzej
Poletajew, Sławomir
Kryst, Piotr
Nyk, Łukasz
author_sort Szempliński, Stanisław
collection PubMed
description Prostate biopsy is recommended in cases of positive magnetic resonance imaging (MRI), defined as Prostate Imaging Reporting and Data System (PIRADS) category ≥ 3. However, most men with positive MRIs will not be diagnosed with clinically significant prostate cancer (csPC). Our goal was to evaluate pre-biopsy characteristics that influence the probability of a csPC diagnosis in these patients. We retrospectively analyzed 740 consecutive men with a positive MRI and no prior PC diagnosis who underwent MRI-ultrasound fusion biopsies of the prostate in three centers. csPC detection rates (CDRs) for each PIRADS category were calculated. Patient, disease, and lesion characteristics were studied for interdependencies with the csPC diagnosis. The CDR in patients with PIRADS categories 3, 4, and 5 was 10.5%, 30.7%, and 54.6%, respectively. On both uni- and multivariable regression models, older age, being biopsy-naïve, prostate specific antigen ≥ 10 ng/mL, smaller prostate volume, PIRADS > 3, a larger maximum lesion size, a lesion in the peripheral zone, and a positive digital rectal examination were associated with csPC. In this large, multicenter study, we provide new data regarding CDRs in particular PIRADS categories. In addition, we present several strong predictors that further alter the risk of csPC in MRI-positive patients. Our results could help in refining individual risk assessment, especially in PIRADS 3 patients, in whom the risk of csPC is substantially low.
format Online
Article
Text
id pubmed-9820960
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-98209602023-01-07 Predictors of Clinically Significant Prostate Cancer in Patients with PIRADS Categories 3–5 Undergoing Magnetic Resonance Imaging-Ultrasound Fusion Biopsy of the Prostate Szempliński, Stanisław Kamecki, Hubert Dębowska, Małgorzata Zagożdżon, Bartłomiej Mokrzyś, Mateusz Zawadzki, Marek Sosnowski, Roman Tokarczyk, Andrzej Poletajew, Sławomir Kryst, Piotr Nyk, Łukasz J Clin Med Article Prostate biopsy is recommended in cases of positive magnetic resonance imaging (MRI), defined as Prostate Imaging Reporting and Data System (PIRADS) category ≥ 3. However, most men with positive MRIs will not be diagnosed with clinically significant prostate cancer (csPC). Our goal was to evaluate pre-biopsy characteristics that influence the probability of a csPC diagnosis in these patients. We retrospectively analyzed 740 consecutive men with a positive MRI and no prior PC diagnosis who underwent MRI-ultrasound fusion biopsies of the prostate in three centers. csPC detection rates (CDRs) for each PIRADS category were calculated. Patient, disease, and lesion characteristics were studied for interdependencies with the csPC diagnosis. The CDR in patients with PIRADS categories 3, 4, and 5 was 10.5%, 30.7%, and 54.6%, respectively. On both uni- and multivariable regression models, older age, being biopsy-naïve, prostate specific antigen ≥ 10 ng/mL, smaller prostate volume, PIRADS > 3, a larger maximum lesion size, a lesion in the peripheral zone, and a positive digital rectal examination were associated with csPC. In this large, multicenter study, we provide new data regarding CDRs in particular PIRADS categories. In addition, we present several strong predictors that further alter the risk of csPC in MRI-positive patients. Our results could help in refining individual risk assessment, especially in PIRADS 3 patients, in whom the risk of csPC is substantially low. MDPI 2022-12-25 /pmc/articles/PMC9820960/ /pubmed/36614957 http://dx.doi.org/10.3390/jcm12010156 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Szempliński, Stanisław
Kamecki, Hubert
Dębowska, Małgorzata
Zagożdżon, Bartłomiej
Mokrzyś, Mateusz
Zawadzki, Marek
Sosnowski, Roman
Tokarczyk, Andrzej
Poletajew, Sławomir
Kryst, Piotr
Nyk, Łukasz
Predictors of Clinically Significant Prostate Cancer in Patients with PIRADS Categories 3–5 Undergoing Magnetic Resonance Imaging-Ultrasound Fusion Biopsy of the Prostate
title Predictors of Clinically Significant Prostate Cancer in Patients with PIRADS Categories 3–5 Undergoing Magnetic Resonance Imaging-Ultrasound Fusion Biopsy of the Prostate
title_full Predictors of Clinically Significant Prostate Cancer in Patients with PIRADS Categories 3–5 Undergoing Magnetic Resonance Imaging-Ultrasound Fusion Biopsy of the Prostate
title_fullStr Predictors of Clinically Significant Prostate Cancer in Patients with PIRADS Categories 3–5 Undergoing Magnetic Resonance Imaging-Ultrasound Fusion Biopsy of the Prostate
title_full_unstemmed Predictors of Clinically Significant Prostate Cancer in Patients with PIRADS Categories 3–5 Undergoing Magnetic Resonance Imaging-Ultrasound Fusion Biopsy of the Prostate
title_short Predictors of Clinically Significant Prostate Cancer in Patients with PIRADS Categories 3–5 Undergoing Magnetic Resonance Imaging-Ultrasound Fusion Biopsy of the Prostate
title_sort predictors of clinically significant prostate cancer in patients with pirads categories 3–5 undergoing magnetic resonance imaging-ultrasound fusion biopsy of the prostate
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9820960/
https://www.ncbi.nlm.nih.gov/pubmed/36614957
http://dx.doi.org/10.3390/jcm12010156
work_keys_str_mv AT szemplinskistanisław predictorsofclinicallysignificantprostatecancerinpatientswithpiradscategories35undergoingmagneticresonanceimagingultrasoundfusionbiopsyoftheprostate
AT kameckihubert predictorsofclinicallysignificantprostatecancerinpatientswithpiradscategories35undergoingmagneticresonanceimagingultrasoundfusionbiopsyoftheprostate
AT debowskamałgorzata predictorsofclinicallysignificantprostatecancerinpatientswithpiradscategories35undergoingmagneticresonanceimagingultrasoundfusionbiopsyoftheprostate
AT zagozdzonbartłomiej predictorsofclinicallysignificantprostatecancerinpatientswithpiradscategories35undergoingmagneticresonanceimagingultrasoundfusionbiopsyoftheprostate
AT mokrzysmateusz predictorsofclinicallysignificantprostatecancerinpatientswithpiradscategories35undergoingmagneticresonanceimagingultrasoundfusionbiopsyoftheprostate
AT zawadzkimarek predictorsofclinicallysignificantprostatecancerinpatientswithpiradscategories35undergoingmagneticresonanceimagingultrasoundfusionbiopsyoftheprostate
AT sosnowskiroman predictorsofclinicallysignificantprostatecancerinpatientswithpiradscategories35undergoingmagneticresonanceimagingultrasoundfusionbiopsyoftheprostate
AT tokarczykandrzej predictorsofclinicallysignificantprostatecancerinpatientswithpiradscategories35undergoingmagneticresonanceimagingultrasoundfusionbiopsyoftheprostate
AT poletajewsławomir predictorsofclinicallysignificantprostatecancerinpatientswithpiradscategories35undergoingmagneticresonanceimagingultrasoundfusionbiopsyoftheprostate
AT krystpiotr predictorsofclinicallysignificantprostatecancerinpatientswithpiradscategories35undergoingmagneticresonanceimagingultrasoundfusionbiopsyoftheprostate
AT nykłukasz predictorsofclinicallysignificantprostatecancerinpatientswithpiradscategories35undergoingmagneticresonanceimagingultrasoundfusionbiopsyoftheprostate